ASP2535 explained

ASP2535 is an inhibitor of the type 1 glycine transporter.[1] It could potentially be used in treatment of Alzheimer's disease and schizophrenia.

Potential uses

ASP2535 has been investigated for the treatment of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent.

Notes and References

  1. Harada . Katsuya . Nakato . Kazuhiro . Yarimizu . Junko . Yamazaki . Mayako . Morita . Masahiko . Takahashi . Shinji . Aota . Masaki . Saita . Kyoko . Doihara . Hitoshi . Sato . Yuichiro . Yamaji . Takayuki . Ni . Keni . Matsuoka . Nobuya . 2012-06-15 . A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease ]. European Journal of Pharmacology . 685 . 1–3 . 59–69 . 10.1016/j.ejphar.2012.04.013 . 1879-0712 . 22542656.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "ASP2535".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.